318 related articles for article (PubMed ID: 27606939)
41. Inhibitors of cyclin-dependent kinase modulators for cancer therapy.
Senderowicz AM
Prog Drug Res; 2005; 63():183-206. PubMed ID: 16265881
[TBL] [Abstract][Full Text] [Related]
42. Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanisms.
Węsierska-Gądek J; Maurer M
Curr Pharm Des; 2011; 17(3):256-71. PubMed ID: 21348827
[TBL] [Abstract][Full Text] [Related]
43. [Prevention of chemotherapy-induced alopecia by cyclin-dependant kinase inhibitors].
Meijer L; Knockaert M; Damiens E
Bull Cancer; 2001 Apr; 88(4):347-50. PubMed ID: 11371368
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of cyclin-dependent kinases - a review of the recent patent literature.
Basso AD; Doll RJ
Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):357-67. PubMed ID: 18221046
[TBL] [Abstract][Full Text] [Related]
45. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors.
Johnson N; Shapiro GI
Expert Opin Ther Targets; 2010 Nov; 14(11):1199-212. PubMed ID: 20932174
[TBL] [Abstract][Full Text] [Related]
46. Whether to target single or multiple CDKs for therapy? That is the question.
Węsierska-Gądek J; Maurer M; Zulehner N; Komina O
J Cell Physiol; 2011 Feb; 226(2):341-9. PubMed ID: 20836132
[TBL] [Abstract][Full Text] [Related]
47. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
Collins I; Garrett MD
Curr Opin Pharmacol; 2005 Aug; 5(4):366-73. PubMed ID: 15964238
[TBL] [Abstract][Full Text] [Related]
48. CDK8 kinase--An emerging target in targeted cancer therapy.
Rzymski T; Mikula M; Wiklik K; Brzózka K
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1617-29. PubMed ID: 26006748
[TBL] [Abstract][Full Text] [Related]
49. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
Senderowicz AM
Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
[TBL] [Abstract][Full Text] [Related]
50. Coming full circle: cyclin-dependent kinases as anti-cancer drug targets.
Fisher RP
Subcell Biochem; 2010; 50():1-15. PubMed ID: 20012574
[TBL] [Abstract][Full Text] [Related]
51. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
Kaubisch A; Schwartz GK
Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
[TBL] [Abstract][Full Text] [Related]
52. Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents.
Dai Y; Grant S
Curr Oncol Rep; 2004 Mar; 6(2):123-30. PubMed ID: 14751090
[TBL] [Abstract][Full Text] [Related]
53. Inhibitors of cyclin dependent kinases: useful targets for cancer treatment.
Sharma PS; Sharma R; Tyagi R
Curr Cancer Drug Targets; 2008 Feb; 8(1):53-75. PubMed ID: 18288944
[TBL] [Abstract][Full Text] [Related]
54. New phosphatidylinositol 3-kinase inhibitors for cancer.
Bowles DW; Jimeno A
Expert Opin Investig Drugs; 2011 Apr; 20(4):507-18. PubMed ID: 21395485
[TBL] [Abstract][Full Text] [Related]
55. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.
Premnath PN; Craig SN; Liu S; Anderson EL; Grigoroudis AI; Kontopidis G; Perkins TL; Wyatt MD; Pittman DL; McInnes C
J Med Chem; 2015 Jan; 58(1):433-42. PubMed ID: 25454794
[TBL] [Abstract][Full Text] [Related]
56. A systematic review on understanding the mechanistic pathways and clinical aspects of natural CDK inhibitors on cancer progression.: Unlocking cellular and biochemical mechanisms.
Asghar A; Chohan TA; Khurshid U; Saleem H; Mustafa MW; Khursheed A; Alafnan A; Batul R; Bin Break MK; Almansour K; Anwar S
Chem Biol Interact; 2024 Apr; 393():110940. PubMed ID: 38467339
[TBL] [Abstract][Full Text] [Related]
57. CDK4/6 inhibitors in breast cancer.
Dukelow T; Kishan D; Khasraw M; Murphy CG
Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
[TBL] [Abstract][Full Text] [Related]
58. CDK inhibitors: from the bench to clinical trials.
Rizzolio F; Tuccinardi T; Caligiuri I; Lucchetti C; Giordano A
Curr Drug Targets; 2010 Mar; 11(3):279-90. PubMed ID: 20210753
[TBL] [Abstract][Full Text] [Related]
59. Selectivity and potency of cyclin-dependent kinase inhibitors.
Sridhar J; Akula N; Pattabiraman N
AAPS J; 2006 Mar; 8(1):E204-21. PubMed ID: 16584130
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of CDKs as a therapeutic modality.
Sausville EA; Johnson J; Alley M; Zaharevitz D; Senderowicz AM
Ann N Y Acad Sci; 2000 Jun; 910():207-21; discussion 221-2. PubMed ID: 10911915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
